

**The World's
Best Business
Opportunity**

**We Are
looking
for**

**Business
Partner**



Selective Business Partner will join our Technical , , development , , medical , financial , certification and registration team for assembly the innovative and advance SoeWound® A Small Portable Device generate Reactive " Energetic Oxygen , specifically design to increase the blood and tissue Oxygenation through inhalation , that help most of chronic wounds to heal and regenerate faster " most of chronic wounds tissues are less in Oxygen concentration saturation 30 less than healthy tissues , that explain why the regeneration is very slow , " Oxygen is one of the main internal factor works in Harmony manner to turn one the regeneration process .. " say's Pr.Dr.Tadros Dcare Canada President "

Our project started in 2019 , in cooperation with UK and Canada Researches and Universities hospital in UK , Canada and USA , with several heath sectors and hundreds of wound care specialist world wide , we are a team of highly motivated to bring to the Gulf and Middle East countries , what we believe is innovative medical devic for all kinds of chronic wounds " say's scantest Neil Stent ford Managing Director and SOE WoundEx Health Ltd



Pr.Dr.Tadros DCare Canada President

www.dcaremedical.ca - info@dcaremedical.ca - + 5878925692



Neil Stentiford , Managing Director , SOE Health Ltd, +44-7957-828891

www.soemac.com - neils@soemac.com



www.soewound.com , neils@soemac.com or soewound@amail.com





WE REGENERATE

SoeWound is designed by Pr. Dr. Ihab Tadros "from the Medical side" who is a leader in Tissue Regeneration. Dr Tadros is the President of DCare Medical - Canada, UK, Middle East & Gulf area. The design was made in co-operation with Mr. Neil Stentiford, Managing Director of SOE Health Ltd.

We have performed several Clinical Trials since 2020, saving hundreds of patients from facing Limb Amputations. Conditions included; Diabetic Foot Ulcers, Venous Ulcers, Bed sores - details at www.dcaremedical.ca Visit this link to watch the video covering cases of Chronic Wounds and Gangrene, cured with the help of SoeWound www.soemac.com/science-of-soewound

We work with UK Universities and Institutions, and Research Centres in Canada, on the Science and Technology. Whilst using the SoeMac Technology, a Recent Study shows an Increase in the Partial Pressure of the Arterial Blood Gases, in particular PO2, which has a direct correlation to increased Tissue Oxygenation. [Link here.](#)

A separate Study using an MRI, showed an increase in Cerebral Blood Flow when using the SoeMac Technology. [Link here.](#)

In Germany, our partner has run a Study on HRV, a key marker of the function of the autonomic nervous system, reflecting the body's ability to adapt to stress and maintain physiological balance. Since breathing patterns and oxygen utilization directly influence HRV, this provides valuable insights into how activated oxygen therapy can enhance recovery, resilience, and overall well-being.



SoeWound[®]



Project Introduction :

We are seeking Investors and Business Partners to join our Project Team, working in Saudi Arabia and the Gulf Markets, with expertise in Technical, Product Development, Medical, Scientific, Financial and Regulatory matters. We will be running Patient Trials, and are looking to open a small facility in Saudi, to assemble and market our revolutionary product, SoeWound, which is used for treating chronic, or non-healing, wounds such as Diabetic Foot Ulcers.

SoeWound® is a small portable device that generates Reactive “Energetic Oxygen” specifically designed to increase the body’s blood flow, and tissue oxygenation, through inhalation, that has been shown to help most chronic wounds heal, and regenerate faster. Most chronic wound tissues suffer from a lack of blood flow and oxygenation, which explains why the regeneration is very slow. “Oxygen is the most important element required for the tissue regeneration process” says Pr. Dr. Tadros, President of DCare Canada.

The project started at the end of 2019, in cooperation with researchers from Canada and the UK, and Medical Professionals from Canada, the USA and the UK, interacting with many wound care professionals worldwide. “The project is ready for the next steps in the Gulf and Middle East countries, by way of establishing an assembly and production entity and presence, and conducting formal Patient Trials” says SoeHealth Ltd and WoundEx Ltd Managing Director, Neil Stentiford.

Project Overview

a. Narrative

Also, a company may want to invest in a new product that take up excess manufacturing or marketing capacity, level out seasonal highs and lows, or simply add to profitability with a proven product. Companies may have the internal skills, and, or they may want to develop their own new products. For the past 10 years, Neil Stentiford, Managing Director of WoundEx Ltd, a UK company, has been developing a new technology and a small number of delivery devices to treat various health conditions. For the past 5 years, Dr. Tadros, Managing Director of DCare, a Canadian company, and a specialist in treating patients with

Licensing involves obtaining permission from a company (licensor) to manufacture and sell one or more of its products within a defined market area. The company that obtains these rights (the licensee) usually agrees to pay a royalty fee to the original owner.

What are the advantages of licensing?

You get access to the experience and know-how of the company that developed the product. This company may be much larger than yours, with development capabilities that you cannot afford in your market area..

Chronic Wounds, eg leg ulcers, diabetic foot ulcers, pressure sores etc. has been working with Neil.

The **SoeWound**[®] technology improves cellular function, and promotes cellular repair and regeneration. Dr Tadros has worked with 120 patients suffering with Chronic Wounds, and achieved successful results. Some are shared in the Supporting Documents section. Dr Tadros is currently treating 8 Patients with Hypoxic Wounds in Egypt, in a final pre-Trial, and is honing the treatment protocols ahead of managing a proposed 100 patient Trial in KSA, in 2025, again with sufferers of these Wounds.

Hypoxic Wounds are nasty and non-healing, usually due to a lack of blood flow to the wound tissues, and delivery of oxygen to the cells. They are often associated with Diabetes sufferers, who have a compromised cardio-vascular system. Without sufficient supply of blood and oxygen to the wound site, the cells will gradually die, and a regular outcome is amputation of a lower limb; toe, foot, leg, hand etc.

SoeWound is manufactured in our UK factory. We have capacity for making 200 each week, and expansion space and equipment to quickly increase this to 1,000 each week, within 3 months. The Supply Chain for each of the components is established, and it would take a further 3 months to increase the capacity to 2,000 units each week, or 100,000 per year.

There is the opportunity to create an assembly and production facility in KSA, or a neighbouring Gulf State, with the suitable partner who we are seeking to provide finance, help organise these trials, and on completion, incorporate into the treatment pathway, and provide management overview of NewCo, and manage the distribution of the **SoeWound**[®] products

b. KSA Statistics

KSA is known for having one of the highest rates of obesity and diabetes in the world, due to genetics and lifestyle, and it is a major health issue.

KSA has a population of 37m people, of which 21m are adults over 25 years of age, and of these, 3.7m have Diabetes. Statistically, each year, 6% of these or 223,000 people will have diabetes related ulcers of the lower limbs, which will result in 55,000 amputations every year – or 150 every single day of the year.

The associated cost of pre-treatment, amputation, and post-treatment is estimated at US \$20k per patient, giving an annual cost to the KSA Ministry of Health in excess of US \$1bn every year. The quality of life for amputees is seriously compromised, and life expectancy much reduced.

This is an increasing problem as diabetes continues to affect more and more people. Another worrying statistic is that approximately 25% of KSA 10 years old kids, are already clinically obese, which is the primary cause of diabetes. Not only is there a problem in KSA right now, it is only going to get worse.

c. Science of the SoeWound® and future work

The existing Science is explained in the attached document. Original research was performed on the SoeMac product, and focussed on Respiratory sufferers, and that project will be revived at a later date, but right now all focus is on the SoeWound. The technology is the same, just the delivery system and health condition are different. Future science work is being considered with a number of European Institutions; Nottingham Trent University (NTU), the Queens Medical Centre Hospital

in Nottingham, the Copenhagen Wound Care Centre in Denmark, Pioneer Wound Care clinics in a number of UK locations.

Objectives include, measuring the cellular function, ATP energy production and increased cellular metabolism when using the SoeWound technology.

d. Regulatory and future work

The SoeWound is currently registered in the UK as a Class I Medical Device - Certificate attached. Certificate of Free Sale to KSA and other Gulf markets are also attached. This is sufficient to commence the KSA Patient Trials. We are working with a specialist Regulatory Consultant in the UK – IMed Ltd, to ensure the **SoeWound®** has robust Regulatory registration in the UK, utilising the results from the Patient Trials information in the proposed KSA work. This will require an increased Technical File, and ISO 13485. All of this information will be used to replicate a similar route in KSA with Saudi FDA registration.

Eventually, we plan to achieve Regulatory approvals; US FDA, European CE, UK CA, and KSA Saudi FDA.

e. Future Trials in other Gulf States

Once the KSA patient trials have been completed, we will need to understand what else is required to allow sales into the other Gulf markets.

f. Financials

Brief summary, details in the attachments;

2025	2026	2027	2028	2029
------	------	------	------	------

Units sold	1,000	12,000	25,000	50,000	100,000
Sales Value	\$1m	\$6m	\$12.5m	\$25m	\$50m
Profit/Loss	\$(0.1)m	\$1.8m	\$4.9m	\$11.3m	\$25m

Assumptions;

1. 100 Patients Trials each year – Products, Consumables, Clinical
 2. Selling and Buying Costs in Plan
 3. Regulatory in KSA and UK are estimated
 4. NewCo Costs, including staff, premises, import & onward distribution costs, professional fees, insurance, marketing, IT etc are all best estimates, and will depend on the size of business and operation we will need
- g. Supporting Documentation and Literature**
- a) Clinical Studies and Patient Outcomes
 - b) Literature Review on Topical Oxygen Therapies
 - c) University of Leicester (UoL) reports on Singlet Oxygen detection from the Tech
 - d) Nottingham Trent University (NTU) reports using GCMS, and Radiation Testing
 - e) SoeWound Science
 - f) Regulatory documents
 - g) Financial Summary



How the project Finance will move

DCare Canada and WoundEx – Will Establish A New Limited L Company in Saudi Arabia or any Country in The GCC with the partnership of The GCC Local Person with Share Capital 51% for the GCC local Investor – and will appointed as

The Company Chairman and Director.

WoundEX will carry 24.5 % of share { and Mr. Neil will act as Technical Director of the the GCC Capital of the company in GCC

DCare will Carry 24.5 % from the share and Dr. Tadros will be the Medical and scientific director of the board team Capital in The GCC established company

NewCo - Gulf Plan

DCare Canada and WoundEX will provide the Factory in Saudi Arabia or any GCC country with :

- 1- All Equipment , Machines , Tools and all what is required for assembly .
 - 2- All Technical files for assembly procedure and the knowhow .
 - 3- All the Scientific File .
 - 4- Marketing and sales plan .
 - 5- Scientific meeting for marking and presentation to the hospital in GCC.
 - 6- Leading the selective makrking and sales tea.
- The above will provide against the 24.% of DCare and 24.5 o WoundEX { we spent 5 years in development and clinical trails

The Investor will provide:

The Factory Location Fully furnished with Spac 300 – 400 SM , Parking is mandatory.

The New Company assembly device for Medical device pluse Exporting and importing of Electronic part used for assembly , plus marketing and distribution of Medical devices with three Share Holders as mentioned above .

4 payment along the year From the date of sign the agreement :

- 1- 400.000 US\$ to be in the New Company Bank account to be used for renting , furnishing , salaries up to all the the Expenses relate to setup the the Factory until ready for the production .
- 2- 100.000 USA \$after 3 months , to be in the new company bank account to be used for Product Certification and Documentation and all paper work required for registration , importing and exporting of **SoeWound®** .
- 3- **300.000 US\$ for Production and Packing of 400 Devices ready packed for sales .**
- 4- **4 Last Payment 200.000 to cover any expenses if needed**

DCare / WoundEx - NewCo - Gulf Plan

Dcare / WoundEx - NewCo - Gulf Plan

		2024	2025	2026	2027	2028
Units sold		1,000	12,000	25,000	50,000	100,000
Selling Price	US \$	1,000	500	500	500	500
Buying Cost	US \$	225	200	190	180	170

US \$000

Total Sales		1,000,000	6,000,000	#####	#####	#####
Product Costs		225,000	2,400,000	4,750,000	9,000,000	#####
Freight & Duty		45,000	480,000	950,000	1,800,000	3,400,000
Margin		730,000	3,120,000	6,800,000	#####	#####

less Operating Costs

Patient Trials;							
	SoeWound Products		45,000	40,000	38,000	36,000	34,000
	Consumables		4,500	4,000	3,800	3,600	3,400
	F&D		9,000	8,000	7,600	7,200	6,800
	Clinical Costs	100 @ \$2,000	200,000	200,000	200,000	200,000	200,000
Regulatory;							
	KSA		50,000	50,000	50,000	50,000	50,000
	UK		100,000	50,000	25,000	10,000	10,000
Travel;							
	Dr Tadros	12 @ \$2,500	30,000	30,000	30,000	30,000	30,000
	Neil Stentiford	6 @ \$2,500	15,000	15,000	15,000	15,000	15,000
	Other	6 @ \$2,500	15,000	15,000	15,000	15,000	15,000
NewCo Costs;							
	Office & Warehouse		12,000	24,000	24,000	24,000	24,000
	Staff	1/2/3/4/5	50,000	100,000	150,000	200,000	250,000
	Management Fees		100,000	200,000	300,000	400,000	500,000
	Insurance		10,000	60,000	125,000	250,000	500,000
	Local Travel / Expenses		10,000	20,000	30,000	40,000	50,000
	Distribution		25,000	150,000	312,500	625,000	1,250,000
	Professional - Lawyer / Accountant		20,000	30,000	30,000	40,000	40,000
	IT / Website / Telecoms		20,000	20,000	25,000	30,000	30,000
	Product Samples		22,500	40,000	57,000	72,000	85,000
	Marketing		25,000	50,000	100,000	200,000	250,000
	Contingency		25,000	150,000	312,500	625,000	1,250,000

Total Operating Costs	788,000	1,256,000	1,850,400	2,872,800	4,593,200
-----------------------	---------	-----------	-----------	-----------	-----------

Profit	-58,000	1,864,000	4,949,600	#####	#####
---------------	----------------	------------------	------------------	--------------	--------------



SoeWound®

Reactive oxygen species (ROS) play a pivotal role in the orchestration of the normal wound-healing response. They act as secondary messengers to many immunocytes and non-lymphoid cells, which are involved in the repair process, and appear to be important in coordinating the recruitment of lymphoid cells to the wound site and effective tissue repair. ROS also possess the ability to regulate the formation of blood vessels (angiogenesis) at the wound site and the optimal perfusion of blood into the wound-healing area. ROS act in the host's defense through phagocytes that induce an ROS burst onto the pathogens present in wounds, leading to their destruction, and during this period, excess ROS leakage into the surrounding environment has further bacteriostatic effects. In light of these important roles of ROS in wound healing and the continued quest for therapeutic strategies to treat wounds in general and chronic wounds, such as diabetic foot ulcers, venous and arterial leg ulcers and pressure ulcers in particular, the manipulation of ROS represents a promising avenue for improving wound-healing responses when they are stalled.





SoeWound[®]

FINALLY

The Smallest , Portable
Reactive Oxygen generator For

Wound Respiration

DCARE
Medical Supply Canada

www.dcaremedical.ca

Designed By Soehealth UK - Manufactured by
M.I.S. Electronics Inc. - Canada

Several factors can impair wound healing such as oxygenation defects, aging, and stress as well as deleterious health conditions such as infection, diabetes, alcohol overuse, smoking and impaired nutritional status.



SoeWound[®]

Growing evidence suggests that reactive oxygen species (ROS) are crucial regulators of several phases of healing processes. ROS are centrally involved in all wound healing processes as low concentrations of ROS generation are required for the fight against invading microorganisms and cell survival signaling. Excessive production of ROS or impaired ROS detoxification causes oxidative damage, which is the main cause of non-healing chronic wounds.

A chronic wound is one that has failed to progress through the phases of healing in an orderly and timely fashion and has shown no significant progress toward healing in 30 days. Factors contributing to the chronicity of the wound may include: Pressure, trauma and/or lower extremity wounds


Increased bacterial load Excessive proteases: Degraded growth factors, matrix metalloproteinases (MMPs), degraded cell surface structures Senescent/Aberrant cells inappropriate treatment





SoeWound[®]

Reactive oxygen species (ROS) play a pivotal role in the orchestration of the normal wound-healing response. They act as secondary messengers to many immunocytes and non-lymphoid cells, which are involved in the repair process, and appear to be important in coordinating the recruitment of lymphoid cells to the wound site and effective tissue repair. ROS also possess the ability to regulate the formation of blood vessels (angiogenesis) at the wound site and the optimal perfusion of blood into the wound-healing area. ROS act in the host's defense through phagocytes that induce an ROS burst onto the pathogens present in wounds, leading to their destruction, and during this period, excess ROS leakage into the surrounding environment has further bacteriostatic effects. In light of these important roles of ROS in wound healing and the continued quest for therapeutic strategies to treat wounds in general and chronic wounds, such as diabetic foot ulcers, venous and arterial leg ulcers and pressure ulcers in particular, the manipulation of ROS represents a promising avenue for improving wound-healing responses when they are stalled.



Thanks

All Technical and Scientific and Clinical trial are available on request and after the agreement is signed

The Investor We are Looking For will be a partner with 51% share capital in the new company in Saudi Arabia and / GCC

The New Company will handle the assembly, Testing, Production, packing , marketing and sales channels along the GCC and Middle East .

Also The New Company will act to issue ISO , Certificate for the products

Plus “ **EN ISO 13485** “ and prepare all the documents required for registration in SFDA , and all health sectors in GCC and Middle East “ part of the documents is the technical file , Scientific , Medical files and the clinical trials done in Canada , UK and Middle East . all files are available just the face to face meeting .